Chapter 16: Antihypertensives

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Right now,

inside your body, there is this microscopic high -stakes tug -of -war happening.

Yeah, literally right now.

Your heart is pumping, your blood vessels are squeezing, and your kidneys are acting like these master control boards, frantically trying to keep the internal pressure in perfect balance.

It's a massive balancing act.

It really is.

And if you are staring down a pharmacology exam, brewing your third cup of coffee, and your own blood pressure is spiking just looking at chapter 16, well, you are in the right place.

Welcome to a special deep dive brought to you by the Last Minute Lecture Team.

We are so glad you're here.

Our mission today is to completely demystify antihypertensives for you.

We are going to take all that dense, intimidating drug data from Lippincott and decode it into plain English.

Exactly, because, you know, knowledge is most valuable when it's deeply understood, not just memorized on flashcards the night before.

Nobody wants to just memorize a list of cells.

Exactly.

So we are going to look at the cellular machinery, connect the foundational physiology to the targets and show you exactly why these medications do what they do.

So let's unpack this from the very top, the baseline numbers, because we hear about blood pressure constantly.

But to treat it, we really need to know what actually qualifies as high.

Right.

So blood pressure is considered elevated when the systolic pressure, that's the top number, right?

The force when the heart actively beats is between 120 and 129.

OK.

While the diastolic, the bottom number, the pressure when the heart is resting between

is less than 80.

You cross the clinical threshold into true hypertension when that systolic number hits 130 or higher, or the diastolic hits 80 or higher.

And crucially for diagnosis, I mean, you can't just take one reading, right?

Those numbers have to be recorded on at least two separate occasions.

Right, exactly.

You could just be nervous at the doctor's office.

White coat syndrome.

Yeah.

So what is actually happening mechanically in the body to make those numbers spike in the first place?

Well, it really comes down to the physical plumbing of your cardiovascular system.

Hypertension is primarily the result of increased arterial or smooth muscle tone.

The arterials.

Right.

The tiny muscles wrapped around your smallest arteries are just squeezing way too tight.

Oh, wow.

Yeah.

And that creates high peripheral resistance,

which is essentially forcing your heart to work overtime just to push blood through these narrowed pipes.

OK.

And this is the part that drives me absolutely crazy about this chapter.

When we look at the etiology, the actual cause of that squeezing,

the textbook says over 90 % of hypertension cases are classified as essential hypertension.

Essential hypertension, yeah.

Which is basically a fancy academic way of saying we have absolutely no idea what causes it.

We really don't.

So how can we have an entire chapter of precision drugs for disease when we don't even know its root origin?

I know.

It is one of the most frustrating yet kind of profound concepts in pharmacology.

For 90 % of patients, we can't point to a single failing organ or like a specific tumor causing the issue.

We just have clues.

Right.

We only know the risk factors.

A family history, advancing age, diabetes, obesity, smoking,

a high sodium diet.

We also see demographic variations with a notably higher incidence in non -Hispanic black populations compared to non -Hispanic white and Hispanic populations.

But the core trigger is a mystery.

Yeah.

But to answer your question, we don't actually need to know the origin of the disease to fix the danger.

Wait, really?

Yeah.

Because if we understand how the body normally regulates blood pressure, we can use targeted chemicals to basically hijack those specific mechanical pathways and artificially force the pressure back down.

So we bypass the broken Y and just manipulate the levers we can reach.

Exactly.

That makes total sense.

So let's look at those levers.

There's a foundational formula in Figure 16 .3 that basically maps out how the body controls blood pressure.

Yeah.

Figure 16 .3 is crucial.

It shows that arterial blood pressure is simply cardiac output multiplied by peripheral resistance.

Cardiac output times peripheral resistance.

Cardiac output is the pump your heart.

It's how fast it beats and the volume of blood it pushes with each strike.

Peripheral resistance is the pipes.

How constricted or relaxed your blood vessels are.

So it's basically pump times pipes.

Exactly.

So to lower blood pressure, you really only have two choices.

You either slow down the pump or you widen the pipes.

Pump and pipes.

Got it.

And the body has two main automatic control systems managing those variables, right?

Looking at Figure 16 .4, the rapid response one is the baroflex system.

Right, the baroflexes.

These rely on a pressure -sensitive neurons called baroreceptors, which are physically embedded in the aortic arch and the carotid sinuses in your neck.

Literally sensors in the neck.

Yep.

If your blood pressure suddenly drops, these sensors instantly decrease their firing rate to the brain.

The central nervous system registers that drop as a total emergency.

And it freaks out.

Exactly.

It triggers the sympathetic nervous system.

It immediately dumps neurotransmitters that tell the blood vessels to constrict, which drives up resistance and tells the heart to beat faster and harder, driving up cardiac output.

I always pictured the baroflex like a really sensitive digital thermostat in your house.

Oh, that's a good way to look at it.

Yeah.

The split second, a cool draft hits, the sensor catches it, and the furnace kicks on instantly to compensate.

Perfect analogy.

But the body also has a slow long -term control system.

Right.

The RAAS.

Yeah.

The renin angiotensin aldosterone system, or RAAS.

This pathway is overseen by the kidneys.

When the kidneys sense low blood pressure, they release an enzyme into the blood called renin.

Renin.

Renin hunts down a protein called angiotensinogen and cleaves it, converting it into a molecule called angiotensin theserve.

Which is just a precursor, right?

Like it has to be transformed again to actually do the heavy lifting.

It does.

So angiotensin I travels through the bloodstream to the lungs where it meets the angiotensin converting enzyme, or ACE.

Ah, ACE.

We hear about that all the time.

ACE turns angiotensin I into angiotensin the second.

And this is a pivotal moment because angiotensin the second is one of the most potent vasoconstrictors in human biology.

It violently clamps down on the blood vessels, sending peripheral resistance and blood pressure skyrocketing.

And angiotensin the second also goes after the fluid volume, doesn't it?

It does.

Like it travels to the adrenal glands and triggers the release of the hormone aldosterone.

And aldosterone basically orders the kidneys to stop making so much urine and instead hoard sodium and water in the body.

Exactly.

You are actively trapping fluid.

So more fluid stuffed into the exact same size pipes means massive pressure.

Right.

So if the Boroflex is the instantaneous digital thermostat,

the RAAS is like the municipal water department adjusting the flow in the city's underground mains.

That's spot on.

It takes hours or days to really shift, but it changes the entire baseline volume of the system.

A perfect analogy.

And practically every drug we prescribe targets either that thermostats wiring or the water department's chemical.

Because our ultimate goal isn't just to make a monitor display a pretty number.

The objective is to reduce cardiovascular and renal morbidity and mortality.

Because high pressure is actually causing physical damage.

Exactly.

Chronic high pressure shreds blood vessels over time, leading directly to heart disease and stroke, which are the top two causes of death globally.

So we generally aim to get patients below that 130 over 80 threshold.

To get them there, the textbook gives us a starting lineup.

If you look at figures 16 .5 and 16 .6, there are four first line classes.

Thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers.

But we don't just throw a dart at the board to pick one.

The text places huge emphasis on concomitant diseases.

Yes, individualized care dictates everything here.

A concomitant disease is a secondary condition the patient already suffers from, like diabetes, heart failure, or previous myocardial infarction, you know, heart attack.

OK, so how does that change the game plan?

Well, a diabetic patient, for example, has incredibly fragile filters in their kidneys.

So that concomitant disease completely dictates which of those four starting drugs you reach for first.

Because you need a drug that lowers blood pressure while actively shielding those kidney filters.

That makes total sense.

So let's get into the actual pharmacology, starting with the diuretics.

Figure 16 .7 maps this out.

If we're looking at the cellular level, their entire mission is decreasing blood volume.

Right.

They basically drain the pool.

Exactly.

Diuretics force the kidneys to excrete sodium and water into the urine.

Less sodium and water retention means your total blood volume drops.

A lower blood volume means the heart has physically less fluid returning to it, which lowers cardiac output, dropping the blood pressure.

We usually start with thiazide diuretics, right?

Like hydrochlorothiazide and chlorothalidone.

We do, but they have a fascinating quirk.

Initially, they lower the blood volume, just like we described.

But with long -term use, the body adapts and blood volume actually returns pretty close to normal.

Wait, really?

Then how do they keep the pressure down?

It's crazy, but their true long -term blood pressure lowering effect is actually due to a sustained decrease in peripheral resistance.

Over time, they somehow tell the smooth muscle in the blood vessels to relax.

Oh, wow.

Yeah.

I didn't know that.

But the catch with thiazides is that they rely on the kidneys being relatively healthy to work, right?

Right.

Except for one specific drug.

Yes.

Metallazone is the exception.

Otherwise, thiazides are basically useless in patients with poor renal function.

You also have to monitor their blood work closely for hypokalemia, which is dangerously because it washes out with the urine,

and hyperuricemia, an accumulation of uric acid that can trigger gout.

Ouch.

So if the patient's kidneys are failing and thiazides won't work, we tag in the heavy hitters, the loop diuretics, like furosemide or torsemide.

Exactly.

Loop diuretics operate in a different part of the kidney anatomy called the loop of Henle.

They brutally block sodium and chloride reabsorption.

So they just force the fluid out.

The clinical distinction here is that they are powerful enough to force even failing kidneys to keep producing urine.

But unlike thiazides, which save calcium, loop diuretics cause the body to dump calcium.

Okay, so they're losing calcium too.

Because they are so aggressive at stripping fluid, we primarily use them to manage the severe fluid buildup of heart failure in edema rather than just everyday hypertension.

Okay, so we know both thiazides and loop diuretics drain potassium out of the body.

So we bring in the third class, right?

The potassium -sparing diuretics, like spironolactone and amylaride.

Exactly.

Because spironolactone is an aldosterone receptor antagonist.

And we said earlier that aldosterone is the hormone that hoards sodium and dumps potassium.

Right.

So by blocking it, spironolactone reverses the effect.

It dumps sodium and hoards potassium.

Which perfectly offsets the potassium loss from the loop diuretics.

Hold on, I want to clarify this clinical interaction because it's so important.

We give a loop diuretic to a patient with a failing heart to clear out all the fluid drowning their lungs.

Yes.

But because that loop diuretic drains their potassium to dangerous levels,

we simultaneously prescribe a potassium -scaring diuretic to balance the scales and keep their electrolytes safe.

That is exactly the clinical logic.

That's brilliant.

And spironolactone brings an incredible secondary benefit.

In heart failure, the heart muscle physically scars, thickens, and changes shape.

A destructive process called cardiac remodeling.

Oh, right.

Spironolactone actively stops that remodeling, protecting the heart from ruining itself.

Wow.

Okay, so we just saw how diuretics drain the fluid volume.

But what if the issue isn't the amount of water, but the pump itself working too hard?

Right.

That takes us to the sympatholetics.

Specifically, the beta -drainoceptor blocking agents.

The beta -blockers.

Figures 16 .8 goes into this.

Yeah, so beta -blockers lower blood pressure primarily by binding to beta -1 receptors right on the heart muscle.

When they block these receptors, they decrease cardiac output by slowing down the heart rate and softening the physical force of every single contraction.

So they calm the pump.

Exactly.

But they have a dual mechanism.

They also block beta -1 receptors located in the kidneys, which completely shuts down the release of renin.

Wait, so they calm the pump and, indeed, they switch off the RAS system at the very first step.

They do.

That is incredible.

But we have to be incredibly careful with the different classes of beta -blockers, right?

Because not all beta -receptors are the same.

No.

And the distinction is literally life or death.

Non -selective beta -blockers, like propranolol, block beta -1 receptors in the heart, but they also block beta -2 receptors, which are predominantly located in the smooth muscle of the lungs.

Meanwhile, selective beta -1 blockers, like metaprolol and atenolol, zero in almost exclusively on the heart.

OK.

So they leave the lungs alone.

Right.

We also have nebivalol, which is highly beta -1 selective but has an added trick.

It triggers the blood vessels to release nitric oxide, a natural chemical that forces vessels to dilate.

Let's follow that logic on the non -selective drugs, because this is a huge test point.

If propranolol blocks beta -2 receptors, and those receptors normally keep the airways in the lungs open and relaxed, giving that to a patient with asthma would basically clamp their airway completely shut.

It would.

It would trigger a massive, potentially fatal bronchospasm.

Their lungs would simply lock up.

That's terrifying.

It is.

This is a classic exam concept.

You must use cardioselective beta -1 blockers if you absolutely have to treat an asthmatic patient.

Good to know.

Really good to know.

So if beta -blockers slow the pump, what do we use to specifically widen the pipes?

This brings us to a massive class, the ACE inhibitors.

The drugs ending in emperol, like captopril and lisinopril, figure 16 .10 shows this perfectly.

Yeah, their mechanism is right in the name.

They inhibit the angiotensin -converting enzyme.

So angiotensin -I never gets turned into the ultravasoconstrictor angiotensin II.

So the signal is stopped.

Without angiotensin II, the vessels stay relaxed, and the adrenal glands stop releasing aldosterone, which means the kidneys stop hoarding sodium and water.

Which takes the pressure off the entire system.

Exactly.

But there is a second half to this mechanism that causes so much clinical drama.

ACE actually has a second job in the body, doesn't it?

Breaking down a peptide called bradycan.

Yes.

Bradycan is a very potent natural vasodilator.

So when you block the ACE enzyme, you don't just stop the production of a constrictor, you also stop the destruction of a dilator.

Oh wow.

So bradycan impiles up in the tissues, leading to massive widespread vasodilation.

Clinically, these cerebrals are superstars.

The text highlights a compelling indication for diabetics, because ACE inhibitors actually dilate the efferent arterial in the kidney.

Yes, that's huge.

They basically widen the exit pipe, which dramatically lowers the physical pressure inside the kidneys' fragile filters, slowing down diabetic kidney disease.

They are amazing for that.

But that buildup of bradycanin we just talked about comes with a notorious adverse effect.

In up to 10 % of patients, mostly women, bradycanin accumulates in the pulmonary tree, irritating the lungs and causing this persistent hacking dry cough.

Oh, the ACE cough.

The ACE cough, exactly.

It's frustrating, but there's a much darker side effect lurking there too, looking at figure 16 .11.

Yes, angioedema.

It is a rare but life -threatening reaction where that same bradycan buildup causes the rapid severe swelling of the lips, tongue, and throat.

That's so dangerous.

It can completely block a patient's airway in minutes.

You also have to monitor these patients for hyperkalemia and remember a strict, non -negotiable rule.

ACE inhibitors are highly teratogenic.

Keratogenic, meaning birth defect.

Yes, they cause severe fetal malformations and must never ever be used in pregnancy.

So we love the blood pressure lowering effect, but we hate the cough and the angioedema risk.

How do we bypass that?

We use the next class, angiotensin II receptor blockers, or ARBs.

The ARBs.

These are the sartans, like low -sartan and herbisartan.

Exactly.

ARBs don't bother with the ACE enzyme at all.

Instead, they travel further down the pathway and physically block the AT1 receptors, which is the exact spot where angiotensin II normally binds to the blood vessels to make them constrict.

Okay, think of it this way.

If angiotensin II is a radio broadcast, an ACE inhibitor basically blows up the radio power so the signal is never sent.

I like that.

But an ARB just unplugs the receiver in your living room.

The signal is still in the air, but the body can't hear it.

That is a phenomenal way to visualize it.

And because ARBs bypass the ACE enzyme entirely, bradykinin is broken down normally.

It never builds up in the lungs.

So no cough.

Therefore, ARBs do not cause the dry cough, and the risk of angioedema just plummets.

But because their end results are so similar, you never combine an ACE inhibitor and an ARB, right?

Yeah.

You're just compounding the side effects with absolutely no added benefit.

Never combine them.

And just like ACE inhibitors, ARBs are strictly teratogenic.

No pregnancy.

Right.

So moving to another strategy for widening the pipes, we have the calcium channel blockers or CCBs.

Muscle cells need an influx of electrical calcium to contract.

If you block the calcium channels on vascular smooth muscle or cardiac muscle, calcium can't get in.

No calcium, no contraction.

The muscles relax.

Figure 16 .12 breaks this down into three chemical classes, and they behave very differently depending on where they like to bind.

The first class is the diphenylalkylamines.

The only drug you really need to know here is verapamil.

It binds strongly to both the heart muscle and the blood vessels.

Because it slows the heart down so significantly, we use it for angina and preventing migraines, but it causes severe constipation, and it can induce a first -degree AV block.

What does that mean?

The AV node is the electrical gateway of the heart.

A block means the electrical signal gets delayed, throwing the heart's rhythm out of sync.

You absolutely avoid verapamil in patients with heart failure because it suppresses the pump way too much.

Okay, so that's class one.

The second class is the benzothiazepines with diltiasm as the prototype.

Right.

Diltiasm sits right in the middle.

It affects both the heart and the vessels, but it has a less aggressive negative inotropic effect, meaning it doesn't weaken the heart's pumping force nearly as much as verapamil does.

Got it.

And the third class is the heavy lifter for standard hypertension, right, the dihydropyridines, the antipines, like amlodipine and nifedipine.

Yes.

The artipones specifically target the calcium channels on the blood vessels, largely ignoring the heart.

They're phenomenal at widening the pipes.

But this leads directly to their adverse effects, which you can see in figure 16 .13.

What happens?

Think of your capillaries like a garden hose with tiny holes.

If you suddenly dilate the arteries feeding into them,

massive pressure hits those tiny vessels and fluid gets forced out into the surrounding tissue.

Oh, wow.

Gravity pulls that fluid down, resulting in peripheral edemaso, severely swollen ankles.

The rapid drop in pressure also causes dizziness, flushing, and headaches.

I also read that nifedipine has a highly specific flash card side effect.

Gingel hyperplasia.

Which is an abnormal overgrowth of the gum tissue in the mouth.

It's very distinct.

So weird.

Let's touch quickly on some of the alternative agents we only pull out when the primary drugs aren't enough, starting with alpha blockers like prozocin and doxazosin.

Right.

So they block alpha -1 receptors to relax the vessels.

The major clinical hurdle here is the first dose effect.

The first dose effect.

When a patient takes their very first pill, it dilates the vessels so aggressively that their blood pressure just plummets.

They experience severe postural hypotension, basically fainting when they try to stand up and reflex tachycardia, where the brain panics at the low pressure and commands the heart to race to compensate.

Not ideal.

We also have the mixed alpha and beta blockers, carvetolol and lebetolol.

They block alpha -1, beta -1, and beta -2 receptors simultaneously.

Yeah.

And carvetolol is an absolute superstar for reducing mortality and heart failure, while is a go -to for managing high blood pressure during pregnancy.

Exactly.

Now, for truly stubborn refractory hypertension, we use centrally acting agents that cross right into the brain.

Oh.

Clonidine is an alpha -2 agonist.

It tells the brain's control center to just dial back the sympathetic nervous system, but you must warn patients if they stop taking clonidine abruptly, the brain rebounds, causing a severe life -threatening spike in blood pressure.

Oh, so they have to taper off.

The other central agent is methyl dopa, which is vital to know because it is considered safe for pregnancy even though it causes significant sedation.

Finally, we reach the direct vasodilators, hydrolazine and minoxidil.

These directly relax smooth muscle.

But wait, if they are so good at widening the pipes, why are they buried at the very back of the chapter instead of being our first choice?

Because the body hates being told what to do.

Naturally.

When you use hydrolazine to forcefully crank the blood vessels wide open, the body's survival mechanisms go into absolute overdrive.

It triggers intense reflex tachycardia to pump more blood, and it orders the kidneys to retain massive amounts of sodium and water to fill those widened pipes.

So to use these drugs, you essentially have to pre -mitigate the side effects.

You prescribe the vasodilator, but you have to add a beta blocker to stop the heart from racing and a diuretic to pee out all the fluid the kidneys are trying to trap.

It's a mandatory chemical cocktail, and they carry bizarre side effects.

Like what?

Hydrolazine can cause a reversible lupus -like syndrome.

The immune system gets temporarily confused and attacks the body's own tissues, causing severe joint pain and a butterfly rash on the face, which clears up once the drug is stopped.

Oh wow.

What about minoxidil?

Minoxidil causes hypertrichosis, which is an excessive growth of thick body hair.

In fact, minoxidil was repurposed and is now the active ingredient in topical treatments for male pattern baldness.

Oh.

I didn't know that's what that was.

Okay, well, last -minute lecture team, it is time to prove what you just learned.

We're pulling two practice questions right from the back of Chapter 16, Question 1.

Which medication can cause the rare side effect of angioedema?

Is it amlodapin, phosphinopril, prazocin, or propranolol?

We can deduce this entirely from this suffix.

The answer is phosphinopril.

Anything ending in amperol is an ACE inhibitor.

By blocking ACE, you stop the breakdown of bradykin.

That bradykin then builds up in the tissues, triggering the severe airway swelling of angioedema.

Spot on.

Question 2.

A diabetic patient post -myocardial infarction with high blood pressure needs an add -on therapy.

What's the best choice, clonidine, omicortin, furosemide, or metoprolol?

The answer is metoprolol.

The key here is the concomitant disease.

The patient just survived a myocardial infarction, a heart attack.

The damaged heart muscle desperately needs to be protected from working too hard.

A selective beta -1 blocker like metoprolol palms the pump directly, satisfying that compelling indication perfectly.

Boom.

As we wrap this up, let's step outside the textbook for just a second.

We just spent this entire deep dive talking about outsmarting the body.

You try an ACE inhibitor if they cough, you switch to an ARB.

But consider the sheer evolutionary brilliance and stubbornness of the human body.

It really is stubborn.

Every single time we invent a chemical to lower blood pressure, your body's baroflexes and RAAS systems try to fight it and raise it back up.

It forces us to use multiple drugs just to outsmart our own survival mechanisms.

It's an incredible battle happening at the microscopic level every single day.

Something to think about as you master these foundational pathways.

To you listening right now, thank you from the Last Minute Lecture team for trusting us with your study session.

You've got the physiology.

You understand the cellular why, and you are going to absolutely crush this exam.

Good luck.

Until next time.